|
44 Companies |
|
74 Products |
|
74 Products |
|
52 Mechanisms of Action |
|
4 Trials |
|
352 News |
|
| «12345678» |
- sirolimus / Generic mfg.
Enrollment change: Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 30, 2013
P1, N=10, Suspended, Sponsor: Children's Hospital of Philadelphia
N=30 --> 10
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change: Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 26, 2013
P1, N=1, Completed, Sponsor: Children's Oncology Group
N=30 --> 10 N=27 --> 1
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion: Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 26, 2013
P1, N=1, Completed, Sponsor: Children's Oncology Group
N=27 --> 1 Active, not recruiting --> Completed
- Enrollment change, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Jun 25, 2013
P=N/A, N=80, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed N=64 --> 80
- ||||| thioguanine / Generic mfg.
Enrollment change: Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 25, 2013
P3, N=254, Completed, Sponsor: Children's Oncology Group
N=64 --> 80 N=158 --> 254
- Trial withdrawal: Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
N=158 --> 254 Recruiting --> Withdrawn
- Enrollment change: Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Recruiting --> Withdrawn N=35 --> 0
- Trial completion: Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy (clinicaltrials.gov) - Jun 9, 2013
P1, N=20, Completed, Sponsor: University of Louisville
N=35 --> 0 Recruiting --> Completed
- || Enrollment closed: Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 5, 2013
P=N/A, N=98, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed Not yet recruiting --> Active, not recruiting
- Kepivance (palifermin) / SOBI, Amgen
Enrollment change: Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant (clinicaltrials.gov) - May 29, 2013
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Not yet recruiting --> Active, not recruiting N=200 --> 0
- Trial termination: Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer (clinicaltrials.gov) - May 19, 2013
P2, N=9, Terminated, Sponsor: University of South Florida
Completed --> Terminated; study not feasible with low accrual. DSMB recommended closure
- Enrollment change: Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer (clinicaltrials.gov) - May 19, 2013
P2, N=9, Terminated, Sponsor: University of South Florida
DSMB recommended closure N=250 --> 9
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Enrollment change, Combination therapy: Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - May 12, 2013
P1/2, N=14, Active, not recruiting, Sponsor: Children's Oncology Group
N=250 --> 9 N=37 --> 14
- Trial termination: Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant (clinicaltrials.gov) - May 10, 2013
P1, N=252, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
N=37 --> 14 Completed --> Terminated; study closed prematurely upon PI's departure from VICC
- Trial initiation date: High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - May 6, 2013
P2, N=451, Completed, Sponsor: Roswell Park Cancer Institute
Completed --> Terminated; study closed prematurely upon PI's departure from VICC Initiation date: Jul 1991 --> Dec 1991
- Trial completion: High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - May 6, 2013
P2, N=451, Completed, Sponsor: Roswell Park Cancer Institute
Initiation date: Jul 1991 --> Dec 1991 Active, not recruiting --> Completed
- Trial completion, HEOR: Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer (clinicaltrials.gov) - Apr 28, 2013
P2, N=750, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- arsenic trioxide / Generic mfg.
Trial initiation date: Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia (clinicaltrials.gov) - Apr 10, 2013
P1/2, N=13, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Initiation date: May 1998 --> Nov 1998
- arsenic trioxide / Generic mfg.
Enrollment change: Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia (clinicaltrials.gov) - Apr 10, 2013
P1/2, N=13, Completed, Sponsor: Washington University School of Medicine
Initiation date: May 1998 --> Nov 1998 N=32 --> 13
- arsenic trioxide / Generic mfg.
Trial completion: Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia (clinicaltrials.gov) - Apr 10, 2013
P1/2, N=13, Completed, Sponsor: Washington University School of Medicine
N=32 --> 13 Active, not recruiting --> Completed
- || DaunoXome (liposomal daunorubicin) / SOBI, Galen
New P3 trial: NOPHO-DBH: Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years (clinicaltrials.gov) - Apr 8, 2013
P3, N=300, Recruiting, Sponsor: Vastra Gotaland Region
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Trial completion: Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer (clinicaltrials.gov) - Mar 20, 2013
P2, N=40, Completed, Sponsor: Cancer Treatment Centers of America
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 12, 2013
P1, N=35, Recruiting, Sponsor: University of Southern California
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Synribo (omacetaxine mepesuccinate) / Teva
Enrollment change: Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia (clinicaltrials.gov) - Mar 6, 2013
P1/2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=20 --> 0
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 27, 2013
P2, N=47, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
N=20 --> 0 Recruiting --> Active, not recruiting
- New P1 trial: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 26, 2013
P1, N=35, Recruiting, Sponsor: University of Southern California
- decitabine / Generic mfg.
New P1 trial: AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 24, 2013
P1, N=54, Recruiting, Sponsor: Alison Walker
- melphalan / Generic mfg.
Trial completion: Melphalan in Patients With Neoplastic Meningitis (clinicaltrials.gov) - Feb 14, 2013
P1, N=6, Completed, Sponsor: Duke University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- dilanubicel (DVX101) / Deverra Therapeutics
Enrollment closed: Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 5, 2013
P2, N=15, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial termination: Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 22, 2013
P2, N=120, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Completed --> Terminated; Administratively complete.
- decitabine / Generic mfg.
Trial termination: Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 21, 2013
P1, N=21, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively complete. Completed --> Terminated; Administratively complete.
- Enrollment change: S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers (clinicaltrials.gov) - Jan 1, 2013
P=N/A, N=3341, Completed, Sponsor: Southwest Oncology Group
Completed --> Terminated; Administratively complete. N=2500 --> 3341
- Trial completion: S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers (clinicaltrials.gov) - Jan 1, 2013
P=N/A, N=3341, Completed, Sponsor: Southwest Oncology Group
N=2500 --> 3341 Active, not recruiting --> Completed
- Trial completion: S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer (clinicaltrials.gov) - Jan 1, 2013
P=N/A, N=1294, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment change: Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov) - Dec 18, 2012
P3, N=420, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=582 --> 420
- | Trial completion: Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov) - Dec 18, 2012
P3, N=420, Completed, Sponsor: National Cancer Institute (NCI)
N=582 --> 420 Active, not recruiting --> Completed
- dilanubicel (DVX101) / Deverra Therapeutics
Enrollment open: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 16, 2012
P=N/A, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Trial completion: Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 10, 2012
P3, N=720, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant (clinicaltrials.gov) - Dec 9, 2012
P2, N=0, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Terminated; low accrual
- cyclosporine / Generic mfg.
Clinical: Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation (clinicaltrials.gov) - Dec 9, 2012
P2, N=0, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Terminated; low accrual Active, not recruiting --> Terminated; low study accrual
- Enrollment change: Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=244, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Terminated; low study accrual N=386 --> 244
- Trial completion: Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=244, Completed, Sponsor: Fred Hutchinson Cancer Research Center
N=386 --> 244 Active, not recruiting --> Completed
- Enrollment change: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - Nov 20, 2012
P2, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed N=30 --> 10
- Campath (alemtuzumab) / Sanofi
Clinical: Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders (clinicaltrials.gov) - Nov 7, 2012
P2, N=35, Completed, Sponsor: University of California, San Francisco
N=30 --> 10 Recruiting --> Completed
- peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease (clinicaltrials.gov) - Nov 7, 2012
P1, N=21, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Recruiting --> Completed
- cyclophosphamide / Generic mfg.
Trial completion: Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders (clinicaltrials.gov) - Oct 23, 2012
P2, N=72, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 8, 2012
P=N/A, N=43, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed N=60 --> 43
- Enrollment change, Metastases: Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer (clinicaltrials.gov) - Oct 8, 2012
P1/2, N=148, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=60 --> 43 N=120 --> 148
- Trial completion, Metastases: Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer (clinicaltrials.gov) - Oct 8, 2012
P1/2, N=148, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=120 --> 148 Terminated --> Completed
- Trial completion: Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 8, 2012
P=N/A, N=68, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Terminated --> Completed Terminated --> Completed